| Points | Position | |
|---|---|---|
| CEF.UP+NIPE (average of all rankings) (2012) | 18.72 | 250/501 |
| Australian RC (2010) | 50.0 | 321/479 |
| CNRS (2008) | 60.0 | 72/336 |
| Ideas discounted recursive impact factor (2012) | 0.08 | 380/396 |
| ISI, JCR SSE, Article Influence Score (2010) | 8.79 | 108/316 |
| ISI, JCR SSE, Impact Factor (2010) | 46.29 | 14/388 |
| Source Normalized Impact per Paper (SNIP) (2011) | 15.34 | 136/476 |
| Article Influence Score (2021) | 1.59 | 110/409 |
| Article Influence Score (2019) | 1.5 | 91/428 |
| Impact Factor (2021) | 4.58 | 82/409 |
| Impact Factor (2019) | 3.56 | 60/440 |
| Impact Factor (5 year) (2021) | 5.21 | 81/409 |
| Impact Factor (5 year) (2019) | 4.57 | 55/428 |
| SJR - Scimago (2021) | 1.32 | 155/558 |
| SJR - Scimago (2019) | 1.45 | 141/549 |
| Count (2021) | 1.0 | 142/659 |
A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials.
Rita Faria,
Manuel Gomes,
David Epstein,
Ian White
vol. 32, 2014, p. 1157-1170.
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis.
Marta O Soares,
Luısa Canto e Castro
vol. 30, 2012, p. 1101-1117.
Cost Effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries
Carlos Gouveia Pinto,
A. Lafuma,
F. Fagnani,
M.J.C. Nuijten,
G. Berdeaux
vol. 19, 2001, p. 255-265.